Pramel Inhibitors
Pramel inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of Pramel proteins, which are part of the Preferentially Expressed Antigen in Melanoma Like (Pramel) family. These proteins are involved in a variety of cellular processes, particularly in the regulation of gene expression and chromatin dynamics. Pramel proteins are thought to play a crucial role during early developmental stages and in the maintenance of cellular identity through their interactions with chromatin remodeling complexes. By influencing the accessibility of chromatin to transcription factors, Pramel proteins contribute to the regulation of genes involved in cell differentiation, growth, and proliferation. Inhibiting Pramel proteins disrupts these essential cellular processes, allowing researchers to explore their precise functions in gene regulation and how they contribute to maintaining cellular homeostasis.
In research, Pramel inhibitors are instrumental in uncovering the molecular mechanisms that underlie developmental biology, cellular differentiation, and epigenetic regulation. By blocking Pramel activity, scientists can investigate how inhibition affects chromatin structure and the expression of genes related to developmental pathways and cellular identity. This inhibition enables detailed studies of the downstream effects on gene networks that Pramel proteins control, offering insights into their role in critical processes such as cell fate determination, tissue development, and the maintenance of pluripotency. Additionally, Pramel inhibitors can reveal how these proteins interact with other chromatin remodelers and transcriptional regulators, helping to map the broader epigenetic landscape that governs cellular function. Through these studies, the use of Pramel inhibitors advances our understanding of chromatin biology, gene regulation, and the molecular foundations of development and differentiation, shedding light on the complex networks that maintain cellular identity and function in diverse biological systems.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor PD98059 explicitly targets the phosphorylation of ERK1/2 in the MAPK pathway. In this pathway, SPRY4 acts as a negative feedback regulator whose expression can be disrupted when ERK1/2 phosphorylation is attenuated. This action can lead to modified activity or expression of PRAME-like proteins, causing downstream effects on cell differentiation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, specifically blocking the phosphorylation of AKT. By doing so, it interrupts the PI3K-AKT-mTOR signaling cascade, making it harder for PRAME-like to mediate its role in inhibiting apoptosis and promoting cell survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that impedes the assembly of the translation initiation complex. This action can affect the rate of synthesis of PRAME-like proteins, thereby altering the overall levels of PRAME-like within the cell. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the 26S proteasome, responsible for the degradation of intracellular proteins. Its action could influence the turnover of PRAME-like or proteins that interact with PRAME-like within the ubiquitin-proteasome system. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an HDAC inhibitor that changes chromatin conformation, thereby affecting the transcriptional activity of genes. PRAME-like, if acting as a gene regulator, may see its activities disrupted by such epigenetic shifts. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNMT inhibitor affects DNA methylation patterns. Since PRAME-like may be involved in regulating gene expression through epigenetic modifications, the action of 5-Azacytidine can alter these regulatory activities. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 targets the bromodomains of BET proteins, disrupting their ability to read acetylated histones. This action could affect PRAME-like if it participates in similar chromatin-reading activities or interacts with BET proteins. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 stabilizes p53 by inhibiting its interaction with MDM2. This action can interfere with PRAME-like activities if it's involved in pathways related to p53, such as cell cycle regulation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 inhibits Src kinase, blocking its downstream effects, including those on proteins like PRAME-like that might be regulated by Src kinase signaling, particularly if it is involved in processes like cellular migration or invasion. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, preventing the phosphorylation of substrates like c-Jun. This can disrupt PRAME-like's possible involvement in stress response pathways that rely on JNK signaling. | ||||||